The Hampton Cannabis ("THC") Expo announces its 7th annual event event on August 1, 2024, at the Shinnecock Nation, will focus on the cannabis industry, emphasizing psychedelics and medical cannabis in chronic disease management. It will bring together industry Leaders, researchers, and practitioners to explore innovative treatments and foster collaborations in integrative medicine.
Event Highlights
Returning special guest Tremaine S. Wright, Chair of the New York State Office of Cannabis Management, will deliver insights on regulatory developments and the future of medical cannabis. Dr. Natanya Wachtel, an award-winning behavioral psychology scientist, will host a panel on "Psychedelics and Cannabis in Integrative Medicine Approaches for Chronic Disease Management."
About Tremaine Wright
Tremaine S. Wright is the Chairwoman of the New York State {NYS) Office of Cannabis Management and a former NYS Assembly member. An attorney, entrepreneur, and activist, Wright has dedicated her career to empowering her community.
About Natanv.a Wachtel
Dr. Natanya Wachtel is an award-winning behavioral psychology scientist focused on integrative wellness and chronic disease management. She is the founder of New Solutions Network and co-founder of evrmore, a mental wellness platform for Gen Z.
About Garv. Bierfriend
Gary Bierfriend is a visionary in business building, entrepreneurship, and institutional knowledge. As the creator and producer of THC Expo, he has successfully adapted the event to reflect industry trends. Bierfriend is also the co-producer of the Palm Tree Music Festival-Southampton, NY which features top artists like Kygo, Swedish House Mafia, and Calvin Harris.
About The HamP-ton Cannabis ("THC") EXP-O
THC Expo (www.CanXpo.com) explores the intersections of cannabis, psychedelics, and integrative medicine. Through annual conferences, CanXpo advances the understanding and acceptance of plant-based therapies in mainstream healthcare, offering a comprehensive day of learning, networking, and exploration of the latest trends and innovations.
Evolving Trends in Psychedelics and Medical Cannabis
Public perception and evolving regulations are pushing psychedelics and medical cannabis into mainstream medical research. Over 50 sites in the U.S. are conducting clinical trials on psychedelics for conditions such as depression and PTSD, with institutions like the Cleveland Clinic and Johns Hopkins leading the way. Opportunities for Networking and Learning
Attendees will have the chance to:
- Engage in Thought-Provoking Discussions: Participate in panel discussions and presentations by leading experts.
- Explore Innovative Products: Visit exhibitor booths showcasing the latest advancements in medical cannabis and psychedelic treatments.
- Network with Industry Leaders: Build relationships with professionals from various sectors, including healthcare, biotech, legal, and investment communities.
The 7th Annual Hamptons Cannabis Event, "PsY.chedelics & Cannabis in Chronic Disease Management: Integrative Medicine AP-P-roaches," reflects a strategic shift to align with the latest trends in medical cannabis and psychedelic therapies. Set for August 1, 2024, at the Shinnecock Nations wholly owned dispensary Little Beach Harvest, Southampton, NY, this event aims to reshape the future of medical cannabis and psychedelics in chronic disease management. More information and registration details are available at canxpo.com.
The event on August 1, 2024, at the Shinnecock Nation, will focus on the cannabis industry, emphasizing psychedelics and medical cannabis in chronic disease management. It will bring together industry Leaders, researchers, and practitioners to explore innovative treatments and foster collaborations in integrative medicine.
Public Support and Legislative Changes Approximately 65% of Americans see therapeutic potential in psychedelics for mental health issues. This rising acceptance is reflected in legislative efforts, such as the 2024 National Defense Authorization Act, which funds psychedelic research for PTSD treatment among veterans. The FDA's new guidelines for psychedelic clinical trials highlight the growing recognition of these substances' potential.
For tickets, click here.